New Hungarian itemized tenders mean a step back in oncology, says pharma

23 October 2017

A new Hungarian regulation has been issued by the National Health Insurance Fund Manager (NEAK), under which from November 1 this year, the oncology therapy patients in given cancer cases can start with the cheapest innovative product only.

The Hungarian Clinical Oncology Society (MKOT) made its opinion clear with regards to the new itemized tender procedure initiated by NEAK. “No medical arguments can defend the planned unification of oncology therapies, the restriction of medicines available today at the oncology treatment centers,” said MKOT chairman Dr Gábor Pajkos.

According to the Hungarian Association of Innovative Pharmaceutical Manufacturers' (AIPM) previously-published professional position this new tender procedure including competition in the case of innovative therapies is a practice that could result in numerous unfavorable consequences in the short and long term to patients, doctors and eventually the entire Hungarian care system.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK